Radiation protection for an ultra-high intensity laser.

Radiological characterisation of an experimental chamber and other areas of an ultra-high intensity laser facility (-terawatt) revealed significant levels of X ray, gamma and neutron radiation. Different techniques were used to detect and measure this radiation: TLD. photographic film, bubble detectors and germanium spectrometry. A test series of radiological measurements was made for 150 laser shots (300 femtoseconds) with energies in the 1 to 20 J range and a target illuminance of 10(19) W.cm2. Gamma dose equivalents in the vicinity of the chamber varied between 0.7 and 73 mSv. The dose equivalent due to the neutron component was evaluated to be 1% of the gamma dose equivalent. The amount of radiation generated depends on the laser energy and the nature of the target. No activation or contamination of the chamber or target holder were observed. Ultra-high intensity lasers are being extensively developed at the present time and the investigations performed demonstrate that it is necessary to take radiological risks into consideration in the design of ultra-high intensity laser facilities and to define personnel access conditions.

Radionuclide and radiation protection data handbook 2nd edition (2002).

This handbook is a reference source of radionuclide and radiation protection information. Its purpose is to provide users of radionuclides in medicine, research and industry with consolidated and appropriate information and data to handle and transport radioactive substances safely. It is mainly intended for users in low and intermediate activity laboratories. Individual data sheets are provided for a wide range of commonly used radionuclides (144 in total). These radionuclides are classified into five different groups as a function of risk level, represented by colours red, orange, yellow, green and blue, in descending order of risk.

A method to assess predominant energies of exposure in a nuclear research centre--Saclay (France).

A study of dosimetric errors is under way within an international collaborative study of cancer risk among workers in the nuclear industry. The objective is to quantify errors in the estimated photon doses to individual organs used for cancer risk estimation. One source of errors is the response of old dosemeters in workplace exposure conditions. As these conditions are not well known, the International Study must rely on expert estimations. This paper describes a method to assess the proportion of the dose from photons in three energy ranges (< 100, 100-300, > or = 300 keV) using the responses under filters of a multi-element dosemeter. The method was tested on experimental and simulated data and provides a good estimate of the proportion of dose from photons below 100 keV, the most critical for dosemeter response. It was applied to personnel readings in one facility, confirming the experts' estimation. Beyond the International Study, the method has implication for the monitoring and protection of workers.

Dose equivalent measurements at a 2.7 GeV proton accelerator and comparison with the Moyer model.

The Moyer model, based on a semi-empirical method validated in the 7.4 to 350 GeV energy range, is generally used to calculate lateral shielding for high energy proton accelerators. Measurements made for the Saclay Synchrocyclotron, Saturne, have enabled the parameters corresponding to a 2.7 GeV model to be studied for different target thicknesses and angles of observation. These studies show how new data have been used to modify the equations of the model.

Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells.

Pygeum africanum extract has been used for more than 20 years in France in patients suffering from benign prostatic hypertrophy (BPH). The extract displays anti-inflammatory activity and inhibits bladder hyperreactivity during the above conditions. However, the mechanism of action of P. africanum extract has never been clearly resolved. It has been recently demonstrated that infiltration by inflammatory cells may be involved in the development of BPH. Certain of these cell types, such as macrophages, are known to produce chemotactic mediators including leukotrienes, and thus may contribute to the development of the disease. In order to investigate the potential effect of P. africanum extract on arachidonate metabolism, we examined its effect in vitro on leukotriene (LT) synthesis in human polymorphonuclear cells stimulated with the calcium ionophore A23187. Two formulations of the extract were tested, one dissolved in DMSO and one aqueous solution obtained after alkalinization (0.1 N; NaOH/acidification (0.1 N; HCl). Neither formulation had any effect on cell viability which was above 95% in both cases. P. africanum extract dissolved in DMSO significantly inhibited the production of 5-lipoxygenase metabolites (5-HETE, 20-COOH LTB4, LTB4 and 20-OH LTB4) at concentrations as low as 3 micrograms/ml (p < 0.01), while the same extract dissolved in NaOH/HCl only exhibited an inhibitory effect at 10 micrograms/ml (p < 0.01). This difference apparently reflects the greater solubility of the active components in the extract in DMSO. The ability of P. africanum to antagonize 5-lipoxygenase metabolite production may contribute, at least in part, to its therapeutic activity in inflammatory component of BPH.

Prevention of human TNF-induced cutaneous Shwartzmann reaction and acute mortality in mice treated with anti-human TNF monoclonal antibodies.

We studied monoclonal antibodies (MoAbs) directed against human tumour necrosis factor (TNF) for their capacity to prevent toxic or lethal effects of TNF. Two experimental models involving recombinant human TNF (rhTNF) in mice were used: the Shwartzmann reaction, and the lethality after D-galactosamine sensitization. Two MoAbs were found to be protective in both models. These MoAbs prevented mortality when given 6 h, 4 h, or 15 min before rhTNF injection but were not effective if given after TNF. In addition, our results point out that in vitro binding and even neutralizing capacities of anti-hTNF MoAbs do not necessarily reflect their protective efficacy in vivo. Therefore, the models studied here might be useful to evaluate anti-h TNF MoAbs before clinical use.

Surface IgA and Fc-alpha receptors on human alveolar macrophages from normal subjects and from patients with sarcoidosis.

Human alveolar macrophages (AM) obtained by bronchoalveolar lavage (BAL) were found to bear cytophilic IgA and Fc alpha-receptors (Fc alpha R) on their surface. The cytophilic IgA belongs to the IgA1 subclass, but unoccupied receptors can be saturated with either IgA1 or IgA2 molecules. Although both polymeric and monomeric forms could attach, binding was about 5-fold greater for the polymers. Both cytophilic IgA and Fc alpha R are sensitive to trypsin and disappear after 18 h of AM culture. An increase in cytophilic IgA was observed on AM from untreated patients with pulmonary sarcoidosis, but not on AM from steroid-treated patients. A significant correlation was found between IgA levels in BAL and the percentage of AM with cytophilic IgA in normal subjects and in steroid-treated sarcoid patients. However, no such relationship was seen among untreated patients. These data suggest that multiple factors may modulate AM surface receptors for IgA. Inflammatory events occurring in the lungs could alter receptor expression and perhaps be of significance in the immunophysiopathology of certain pulmonary diseases.

Cutaneous IgA subclasses in dermatitis herpetiformis and linear IgA disease.

The subclasses of the cutaneous IgA were studied in 8 patients with dermatitis herpetiformis and 4 with linear IgA disease. The cutaneous IgA in dermatitis herpetiformis consisted of both IgA1 and IgA2, although IgA1 predominated. This demonstrated that the IgA is polyclonal and may be both mucosal and blood derived. The IgA in linear IgA disease was exclusively IgA1, confirming previous work, and suggesting that mucosal IgA may not make a major contribution to the skin deposits.

Massive plasma cell infiltration of the digestive tract. Secretory component as the rate-limiting factor of immunoglobulin secretion in external fluids.

A 29-yr-old Tunisian man had a clinical immunoproliferative small intestinal disease, different from alpha-chain disease. Serum contained 52.5 mg/ml of polymeric immunoglobulin A (IgA). Immunohistochemistry revealed a massive diffuse polyclonal IgA (99%)-plasma cell infiltration in the small bowel mucosa, with a smaller increase of IgA-producing cells in gastric and colonic mucosae. Secretory IgA levels were normal in jejunal and bronchoalveolar secretions. However, both fluids contained polymeric IgA devoid of secretory component, and free secretory component was absent. This suggests that secretory component was the limiting factor in transport of IgA in the secretions. A relative deficiency in secretory component, as compared with the huge supply of polymeric IgA, may have limited the secretory component-mediated active transport of IgA into secretions. This resulted in the appearance of high levels of polymeric IgA, unlinked to secretory component, both in serum and in the jejunal and bronchoalveolar fluids.

Antiproteases are increased in bronchoalveolar lavage in interstitial lung disease.

The present study evaluates different cellular and soluble components in the bronchoalveolar lavage (BAL) from patients with interstitial lung disease. We observed an increased T4/T8 lymphocyte ratio in BAL but not in blood from 24 patients with active pulmonary sarcoidosis compared to sixteen normal individuals and to eleven patients with inactive pulmonary sarcoidosis. Seven patients with hypersensitivity pneumonitis had a normal T4/T8 ratio. In the active sarcoidosis and hypersensitivity pneumonitis groups, alpha 1-Protease Inhibitor (alpha 1 PI) in BAL is significantly higher than in the normal group and a significant correlation between the two antiproteases (alpha 2-macroglobulin and alpha 1 PI) is observed. These data demonstrate that antiprotease levels (alpha 1 PI and alpha 2 M) are increased in the lower respiratory tract of patients with interstitial lung disease and that among cellular and soluble components of BAL, alpha 2 M represents a sensitive marker of the alveolitis.

A polymeric IgA response in serum can be produced by parenteral immunization.

The magnitude and the kinetics of the serum-specific polymeric (p-) and monomeric (m-) IgA antibody responses were analysed following parenteral stimulation with tetanus toxoid (TT) vaccine in 10 volunteers, 5-20 years after a previous boost. A rapid marked serum IgA antibody response involving both the monomeric and polymeric components of IgA was observed: m-IgA and p-IgA antibodies reached a peak of serum activity at about 11 days, around 6 days before the peak of IgG antibody activity. At the peak of the IgA response, p-IgA accounted for approximately half of the anti-TT activity (median 54%, 25-79%). However, p-IgA antibodies rapidly disappeared from serum over a few weeks, whereas the serum m-IgA antibody response was maintained over a prolonged period of time. For one subject out of five, anti-TT IgA were also detected in saliva with a peak of activity earlier than in serum. Calculation of the albumin relative coefficient of excretion for anti-TT IgA in this saliva suggested a local synthesis of these antibodies. The present study indicates that a polymeric IgA antibody response in serum can be produced by parenteral immunization in primed individuals, and it raises the question of the mechanisms that control polymeric versus monomeric IgA production.

Kinetics of anti-Campylobacter jejuni monomeric and polymeric immunoglobulin A1 and A2 responses in serum during acute enteritis.

The intensity and kinetics of the serum polymeric and monomeric immunoglobulin A1 (IgA1) and IgA2 antibody responses to Campylobacter jejuni were analyzed. A rapid and marked serum IgA antibody response involving both the monomeric and polymeric components of IgA was observed after C. jejuni infections. IgA antibodies reached a peak of activity in serum during week 2 after the first symptoms of enteritis, about 10 days before the peak of IgG activity. Polymeric IgA accounted for most of the anti-C. jejuni activity at the peak of the IgA response (median, 90%; range, 44 to 98%) but rapidly disappeared from serum over a few weeks. In contrast, the serum monomeric IgA antibody response was low and was maintained over a prolonged period of time. Anti-C. jejuni IgA detected in the serum of healthy blood donors was mainly monomeric (median, 83%; range, 17 to 94%). In both the patients and the positive controls, IgA1 was the predominant (greater than 85%) subclass involved, even when the IgA antibody response was mainly polymeric. Our results suggest that polymeric IgA antibody responses are linked to a strong or persisting antigenic stimulation or both. Polymeric IgA antibodies appear to be a potential marker of acute C. jejuni infections, and their determination could provide a useful tool for the serological diagnosis of recent C. jejuni infections.

Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense?

Immunoglobulin A has long been referred to as the antibody of mucosal secretions. However, in the last few years there has been increased interest in serum IgA, in factors that regulate the various forms of IgA produced, and in the relationship between serum and mucosal IgA. Recent data indicate that in humans, the mucosal surfaces are neither the source nor the destination of serum IgA. By estimating the amounts of IgA produced at various sites throughout the body, we have shown that in humans more IgA is synthesized and secreted each day than IgG and IgM combined; about one third of this IgA is secreted directly into the vascular compartment and never reaches the mucosal surfaces. We also consider a possible role for serum IgA as the "discreet housekeeper," the relationship between cells that produce IgA in the serum and IgA in secretions, and factors that influence the various forms of IgA produced.

IgA-induced chemokinesis of human polymorphonuclear neutrophils: requirement of their Fc-alpha receptor.

The influence of purified human immunoglobulins on the migration of human neutrophils (PMN) was measured in a 48-well micro chemotaxis chamber, with results expressed as percentages of maximal formyl-methionyl-leucyl-phenylalanine (FMLP)-stimulated chemotaxis. Both monomeric and polymeric IgA, of both subclasses, in monoclonal and polyclonal form, as well as secretory IgA and Fc-alpha, but not Fab-alpha fragments, enhanced PMN migration when present either in the lower or in both compartments of the chamber (chemokinesis) at concns as low as 0.1 mg/ml. IgM and IgE had no such effect. In contrast, IgG was chemotactic at low concn (0.1 mg/ml). Both monomeric and polymeric IgA decreased the maximally induced FMLP-chemotaxis, but IgA increased chemotaxis induced by suboptimal levels of FMLP. Binding of 3[H]-FMLP to PMN was not affected. Cytofluorographic analysis revealed that, under the conditions of the assay, IgA did bind to 93% of PMN. Thus, the various forms of IgA have a dual effect on human PMN mobility: (1) increase PMN random migration (chemokinesis); and (2) decrease the maximal FMLP-induced chemotaxis. Our data support the requirement of binding of IgA to the Fc-alpha receptor of PMN for expression of these activities. This effect of IgA on PMN mobility may be relevant in IgA deficiency states.

Characteristics of serum IgA and liver IgA deposits in alcoholic liver disease.

Patients with alcoholic liver disease frequently reveal an increase in IgA serum concentration and IgA deposits in a continuous pattern along hepatic sinusoids. We investigated whether the hepatic IgA deposits are a passive reflection of changes in concentration or composition of IgA in the circulation, or represent a distinct effect of alcohol on the liver. Forty-one patients with alcoholic liver disease (daily alcohol intake at least 50 gm for more than five consecutive years) were compared with 41 patients with nonalcoholic liver disease. Patients in both groups were matched for serum IgA and histopathological changes in the liver biopsy. IgA deposits in the liver were found in 78% of the alcoholic patients and in 12% of the nonalcoholic patients. The presence of deposits was not related to histopathological changes in the liver or to the serum IgA concentration. In serum IgA subclass distribution, alcoholic patients differed from nonalcoholic patients by a slight but significant shift to IgA2; in contrast, the hepatic IgA deposits in alcoholic patients were almost of the IgA1 subclass. Serum secretory component (which is an equivalent of serum secretory IgA) was elevated in both alcoholic and nonalcoholic patients; patients with a liver biopsy revealing hepatitis showed the highest level. In contrast, the hepatic deposits did not contain secretory component. We conclude that the continuous deposits of IgA along liver sinusoids are not a passive reflection of changes in concentration or composition of circulating IgA, but may represent a distinct effect of alcohol on the liver related to the role of this organ in IgA metabolism.